CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Idera Pharmaceuticals, Inc. (Nasdaq: IDRA), today announced that it will provide an overview of its drug discovery and development programs targeted to Toll-like Receptors and a general corporate update at the 13th Annual BIO CEO & Investor Conference on Monday, February 14, 2011 at 4:00 p.m. ET at the Waldorf=Astoria in New York City.
The live audio webcast presentation will be available in the Investor section of the company’s website at www.iderapharma.com. Archived replays will also be available on the company’s site for two weeks following the event. Please log in approximately 10 minutes prior to the presentation to ensure a timely connection.
About Idera Pharmaceuticals, Inc.
Idera Pharmaceuticals develops drug candidates to treat chronic hepatitis C virus infection, autoimmune and inflammatory diseases, cancer, and respiratory diseases, and for use as vaccine adjuvants. The company's proprietary drug candidates are designed to modulate specific Toll-like Receptors, which are a family of immune system receptors. Idera's pioneering DNA and RNA chemistry expertise enables us to create drug candidates for internal development and generates opportunities for multiple collaborative alliances. For more information, visit www.iderapharma.com.
KEYWORDS: United States North America Massachusetts New York
INDUSTRY KEYWORDS: Health Biotechnology Clinical Trials Infectious Diseases Pharmaceutical